Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - December 2016


For our last newsletter of 2016, we have some exciting and significant news regarding the Company. On December 15th, Cyprotex PLC was acquired by Evotec AG ( Our facilities in the UK (Macclesfield and Alderley Park) and the US (Watertown, MA and Kalamazoo, MI) will all function as usual under the Cyprotex brand, and we will continue to offer industry leading in vitro and in silico services and innovations. However, our customers will now have access to Evotec’s integrated and standalone drug discovery services including medicinal chemistry, structural biology and in vitro and in vivo pharmacology services as well as specialist expertise in key therapeutic areas such as neuroscience, pain, metabolic diseases, oncology, immunology and inflammation, respiratory and anti-infectives. The combined entity will allow our customers to benefit from an enhanced portfolio of services managed seamlessly by our expert scientists.

Earlier this year, Cyprotex launched a suite of non-GLP and GLP genotoxicity services. The in vitro chromosomal aberration test was one of these services. Cyprotex Scientist Jessica Sinha presents on this assay, including its significance in a variety of different industries, such as cosmetics and personal care, chemicals, and pharmaceuticals. Causes and mechanisms of chromosomal aberration, its detection, and testing requirements are discussed in detail.

Finally, we would like to thank you for another great year, and wish you a happy and healthy holiday season and a successful year ahead.

Evotec AG acquires Cyprotex PLC

In December, Cyprotex was acquired by Evotec. Find out more about the acquisition and how you can benefit from our combined offering.

Read the press release

Watch our presentation on in vitro chromosomal aberration

Jessica Sinha from our Kalamazoo site presents on the in vitro chromosomal aberration test including regulatory requirements, types of chromosomal aberration, testing methodology and its relevance in genotoxicity testing.

Watch the presentation

Chromosomal aberration testing
Seasons greetings from Cyprotex

We hope you enjoy the holiday season, and we look forward to working with you in 2017.

Season's greetings from Cyprotex
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.